Verition Fund Management’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-400,000
| Closed | -$16.1M | – | 2092 |
|
|
2026
Q1 | $16.1M | Buy |
+400,000
| New | +$8.62M | 0.1% | 194 |
|
|
2025
Q3 | – | Sell |
-95,605
| Closed | -$1.65M | – | 3741 |
|
|
2025
Q2 | $1.65M | Sell |
95,605
-14,905
| -13% | -$276K | 0.01% | 2091 |
|
|
2025
Q1 | $2.42M | Buy |
110,510
+60,100
| +119% | +$1.66M | 0.01% | 1442 |
|
|
2024
Q4 | $1.61M | Buy |
+50,410
| New | +$1.52M | 0.01% | 1708 |
|
|
2023
Q3 | – | Sell |
-3,997
| Closed | -$364K | – | 2329 |
|
|
2023
Q2 | $364K | Buy |
3,997
+347
| +10% | +$29.9K | ﹤0.01% | 1418 |
|
|
2023
Q1 | $241K | Buy |
+3,650
| New | +$211K | ﹤0.01% | 1659 |
|
|
2022
Q3 | – | Sell |
-5,259
| Closed | -$238K | – | 3034 |
|
|
2022
Q2 | $238K | Sell |
5,259
-47,640
| -90% | -$2.17M | ﹤0.01% | 1845 |
|
|
2022
Q1 | $2.69M | Sell |
52,899
-31,594
| -37% | -$1.39M | 0.03% | 752 |
|
|
2021
Q4 | $4M | Buy |
+84,493
| New | +$3.33M | 0.03% | 467 |
|
|
2021
Q3 | – | Sell |
-19,477
| Closed | -$1.23M | – | 1878 |
|
|
2021
Q2 | $1.23M | Buy |
19,477
+5,375
| +38% | +$277K | 0.01% | 713 |
|
|
2021
Q1 | $605K | Buy |
+14,102
| New | +$667K | 0.01% | 770 |
|
|
2020
Q3 | – | Sell |
-99,045
| Closed | -$3.23M | – | 1048 |
|
|
2020
Q2 | $3.23M | Buy |
99,045
+57,656
| +139% | +$1.85M | 0.11% | 152 |
|
|
2020
Q1 | $1.11M | Buy |
41,389
+18,506
| +81% | +$657K | 0.04% | 230 |
|
|
2019
Q4 | $701K | Buy |
+22,883
| New | +$633K | 0.01% | 554 |
|
Other funds holding APLS
Verition Fund Management's APLS Position: Q2 2026 in Review
Verition Fund Management sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 400,000 shares — an estimated $16.1M sold.
Verition Fund Management first reported a position in APLS in Q4 2019 and held it in 14 quarters. The position peaked at $16.1M in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- Verition Fund Management reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Verition Fund Management sold 400,000 Apellis Pharmaceuticals shares in Q2 2026, an estimated $16.1M.
- Verition Fund Management first reported a position in Apellis Pharmaceuticals in Q4 2019 and held it in 14 quarters.
- Verition Fund Management's Apellis Pharmaceuticals position peaked at $16.1M in Q1 2026.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on Verition Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.